(355)Boldenone undecylenate 250mg
History:
In 1949, Boldenone was reportedly patented by Ciba. In 1950 and 1960 the esters of the compounds were developed by the company. In 1960, one such ester, boldenone undecylenate was introduced for clinical use as an injectable AAS Under the brand name Parenabol. However, in the late 1970s, it was discontinued for use in humans. Squib introduces boldenone undecylenate for veterinary medicine use under the brand name Equipoise. The medication has been used much more widely in veterinary medicine, in which it has been used mainly in horses, and remains in use today. But now a day this medicine becomes more advanced and improved, it is used for the rapid muscle mass gain in human
Boldenone undecylenate 250mg is a veterinary injectable steroid. It is a derivative of testosterone, which exhibits strong anabolic and moderately androgenic properties. The undecylenate ester greatly extends the activity of Boldenone undecylenate 250mg (the undecylenate ester is only one carbon atom longer than decanoate), so that clinically injections need to be repeated every three or four weeks. In the veterinary field Equipoise is mostly used on horses, exhibiting a pronounced effect on lean bodyweight, appetite and general disposition of the animal. As with all steroids, this compound shows a marked ability for increasing red blood cell production. In recent years this compound has become a favorite among athletes. Many consider it an ideal substitute for Deca-Durabolin. Equipoise is not a rapid mass builder but will provide a slow but steady gain of strength and quality muscle mass. The most positive effects of Boldenone undecylenate 250mg are seen when it is used for longer cycles, usually lasting at least 10 weeks in length. The muscle gained should not be the smooth bulk seen with androgens, but instead a very defined and solid look.
Pharmacodynamics:
as the boldenone undecylenate is a prodrug of boldenone, and so it is an agonist of the androgen receptor. It has a moderate androgenic effect and strong anabolic effects.its has little or no progesterone activity and very low estrogenic activity. In relation to the fact that it is not 17 α – alkylated boldenone and boldenone undecylenate have little or no risk of hepatotoxicity.
Pharmacokinetics:
When boldenon undecylenate is administered via intramuscular injection a depot is formed from which boldenone undecylenate is slowly released into the body and then transformed into boldenone. BU is reported to possess a biological half-life of 14 days when administered by intramuscular injection. Boldenone is a substrate for 5 α – reductase and may be converted by this enzyme into 1 – testosterone (δ1 - dihydrotestosterone, δ1 - DHT, dihydroboldenone) in tissues that express it such as the skin, hair, follicles, and prostate gland. However, its affinity for this enzyme is said to be extremely low.
Uses of Boldenone undecylenate 250mg
In order to maintain stable blood levels, Equipoise should be injected at least once per week. It is most commonly used at a dosage of 400-600mg Boldenone undecylenate 250mg per week for men, 50-150 mg Boldenone undecylenate 250mg per week for women.
Contents Boldenone undecylenate 250mg
250mg/ml Boldenone undecylenat (10ml VIAL)
Chemical names Boldenone undecylenate 250mg
1,4 androstadiene-3-one,17beta-ol, 1-dehydrotestosterone
Possible side effects Boldenone undecylenate 250mg
The side effects of Equipoise are generally mild. The structure of Boldenone undecylenate 250mg does allow it to convert into estrogen, but it does not have an extremely high affinity to do so. If we look at aromatization studies, they suggest that its rate of estrogen conversion should be about half that of testosterone’s. Water retention with Boldenone undecylenate 250mg would therefore be slightly higher than that with Deca-Durabolin (with an estimated 20% conversion), but much less than we would find with a stronger compound as Testosterone. While there is still a chance of encountering an estrogen related side effect as such when using Equipoise, problems are usually not encountered at a moderate dosage level. Gynecomastia might become a problem, but usually only with very sensitive individuals or (again) with those using higher dosages. If estrogenic effects become a problem, the addition of Nolvadex should of course make the cycle more tolerable. An anti-aromatase such as Arimidex, Femara, or Amonasin would be a stronger option, however probably not necessary with such a mild drug.
Oily skin – low by Boldenone undecylenate 250mg
acne – low by Boldenone undecylenate 250mg
hair loss – low by Boldenone undecylenate 250mg
Mood changes- aggression – low by Boldenone undecylenate 250mg
paranoia, depression – low by Boldenone undecylenate 250mg
Water retention – low by Boldenone undecylenate 250mg
